Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 58.2% Aware of DTC Disease Education Ads
January 29, 2007
- R&DNEWS IN BRIEF
January 29, 2007
- Globalization Essential to Growth of Domestic Bioventures: Mr Yamazaki
January 29, 2007
- Novartis Begins Independent Sale of OTC Drugs
January 29, 2007
- Life Science to Account for 10-15% of Sales at Toyobo in 2010
January 29, 2007
- SELF-MEDICATION NEWS IN BRIEF
January 29, 2007
- BUSINESS NEWS IN BRIEF
January 29, 2007
- Nichi-Iko Aims at Sales of \43.0 Bil. in 2009
January 29, 2007
- Burgeoning Market for ARBs -Hot Battlefield for Megapharmas- Part 3
January 29, 2007
- Sawai to Provide Add'l Data on Generics to Alleviate Doctors' Concerns
January 29, 2007
- Prefectural Health Administration Officials' Meeting
January 29, 2007
- Wholesalers Could Play Major Role in Popularizing GE Drugs: Report
January 29, 2007
- Drug Evaluation Forum Begins -Drug Makers, PMDA, Academics to Exchange Opinions-
January 29, 2007
- Korosho to Announce Results of Survey on Use of Generics
January 29, 2007
- Chuikyo Approves NHI Price Listing for Alimta, Doxil
January 29, 2007
- Sysmex Develops in Vitro Diagnostic Technology for Cancers
January 29, 2007
- REGULATORY NEWS IN BRIEF
January 29, 2007
- Korosho Proposes "Medical Device MR System"
January 29, 2007
- Development of Amlodipine + Atorvastatin Combination Underway in Japan: Pfizer
January 29, 2007
- MEDICAL DEVICE NEWS IN BRIEF
January 29, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…